- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New Strategies for Long-Term Follow-Up of Gene Therapies: Leveraging virtual approaches and real world data
***Tuesday, November 17, 2020 11am EST | 5pm CET *** Cell and gene therapies hold great promise for long-term or life-threatening illnesses. One of the biggest challenges for sponsors is long-term follow-up (LTFU) of patients -- the need to monitor outcomes and safety for up to 15 years. ***On demand available after final airing until Nov. 17, 2021***
Register free: https://www.pharmexec.com/pe_w/gene_therapies
Event Overview:
Cell and gene therapies have the potential to transform the lives of patients with long-term or life-threatening illnesses. While there is great promise, bringing these new therapies to market is far from simple. One of the biggest challenges is the required long-term follow-up (LTFU) – the need to monitor patient outcomes and safety for up to 15 years.
LTFU is required whether the patient has received therapy through a clinical trial or as an approved product. Traditional approaches to LTFU often mean burden on patients and sites over time. New technologies and virtual tools enable new clinical trial and real world study models to capture rich, clinically relevant endpoints while offering flexibility and convenience for patients, their families, and healthcare providers. New direct-to-patient and data technologies (such as natural language processing) are helping to enrich and scale existing patient registries.
Join our webinar and learn new long-term follow-up strategies you can implement for cell and gene therapies today, with planned evolution for years into the future.
Key Learning Objectives:
- Challenges in conducting long-term follow-up studies for cell and gene therapies
- Flexible virtual and hybrid approaches to LTFU studies that can reduce risk and improve the patient experience
- Options to leverage and supplement existing registries data for long-term evidence generation
Speakers: Monica Shah, MD, FACC, Vice President and Head, Cell and Gene Therapy Center of Excellence, IQVIA
Erin Finot, MS, MBA, Global Head of Immuno-oncology, IQVIA Biotech
Elizabeth Powers, MBA, Vice President, Real World Solutions, IQVIA
Christopher Varner, Project Manager, Virtual Trial Solutions, IQVIA
Time and Date: Tuesday, November 17, 2020 11am EST | 5pm CET
On demand available after final airing until Nov. 17, 2021
Register free: https://www.pharmexec.com/pe_w/gene_therapies
